KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Operating Margin: 2010-2025

Historic Operating Margin for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to 33.10%.

  • Emergent BioSolutions' Operating Margin rose 1115.00% to 33.10% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.02%, marking a year-over-year increase of 3055.00%. This contributed to the annual value of -10.42% for FY2024, which is 5881.00% up from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Operating Margin is 33.10%, which was up 2,815.09% from 1.14% recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Operating Margin high stood at 39.13% for Q4 2021, and its period low was -407.00% during Q2 2024.
  • Over the past 3 years, Emergent BioSolutions' median Operating Margin value was -4.88% (recorded in 2024), while the average stood at -54.71%.
  • As far as peak fluctuations go, Emergent BioSolutions' Operating Margin tumbled by 32,032bps in 2024, and later skyrocketed by 40,814bps in 2025.
  • Emergent BioSolutions' Operating Margin (Quarterly) stood at 39.13% in 2021, then plummeted by 5,588bps to -16.75% in 2022, then skyrocketed by 91bps to -15.84% in 2023, then spiked by 1,096bps to -4.88% in 2024, then soared by 1,115bps to 33.10% in 2025.
  • Its Operating Margin was 33.10% in Q3 2025, compared to 1.14% in Q2 2025 and 22.46% in Q1 2025.